Steady progress over four decades toward understanding the pathogenesis and clinical
consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet …

The benzene moiety is the most prevalent ring system in marketed drugs, underscoring its
historic popularity in drug design either as a pharmacophore or as a scaffold that projects …

Background Conventional preclinical models often miss drug toxicities, meaning the harm
these drugs pose to humans is only realized in clinical trials or when they make it to market …

For decades, preclinical toxicology was essentially a descriptive discipline in which
treatment-related effects were carefully reported and used as a basis to calculate safety …

Abstract Background & Aims Preclinical identification of compounds at risk of causing drug
induced liver injury (DILI) remains a significant challenge in drug development, highlighting …

Nonclinical rodent and nonrodent toxicity models used to support clinical trials of candidate
drugs may produce discordant results or fail to predict complications in humans, contributing …

Microphysiological systems (MPSs) are in vitro models that capture facets of in vivo organ
function through use of specialized culture microenvironments, including 3D matrices and …

In 2011, AstraZeneca embarked on a major revision of its research and development (R&D)
strategy with the aim of improving R&D productivity, which was below industry averages in …

Nonclinical testing has served as a foundation for evaluating potential risks and
effectiveness of investigational new drugs in humans. However, the current two‐dimensional …

We report the development, automation and validation of a 3D, microfluidic liver-on-a-chip
for high throughput hepatotoxicity screening, the OrganoPlate LiverTox™. The model is …